Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human Glypican 3 Anticorps:
anti-Mouse (Murine) Glypican 3 Anticorps:
anti-Rat (Rattus) Glypican 3 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal Glypican 3 Primary Antibody pour ICC, IHC (fro) - ABIN335359
Couchman, Ljubimov, Sthanam, Horchar, Hassell: Antibody mapping and tissue localization of globular and cysteine-rich regions of perlecan domain III. dans The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1995
Show all 7 Pubmed References
Human Polyclonal Glypican 3 Primary Antibody pour CyTOF, FACS - ABIN4899915
Sawada, Yoshikawa, Nobuoka, Shirakawa, Kuronuma, Motomura, Mizuno, Ishii, Nakachi, Konishi, Nakagohri, Takahashi, Gotohda, Takayama, Yamao, Uesaka, Furuse, Kinoshita, Nakatsura: Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. dans Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Show all 3 Pubmed References
Human Polyclonal Glypican 3 Primary Antibody pour IHC (p), WB - ABIN4369853
Lai, Sandhu, Yu, Han, Moser, Jackson, Guerrero, Aderca, Isomoto, Garrity-Park, Zou, Shire, Nagorney, Sanderson, Adjei, Lee, Thorgeirsson, Roberts: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. dans Hepatology (Baltimore, Md.) 2008
Show all 3 Pubmed References
Human Monoclonal Glypican 3 Primary Antibody pour ICC, FACS - ABIN969523
Zittermann, Capurro, Shi, Filmus: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. dans International journal of cancer. Journal international du cancer 2010
Show all 2 Pubmed References
Human Polyclonal Glypican 3 Primary Antibody pour IHC, ELISA - ABIN1585811
Magistri, Leonard, Tang, Chan, Lee, Sicklick: The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. dans The Journal of surgical research 2014
Cow (Bovine) Polyclonal Glypican 3 Primary Antibody pour IHC, WB - ABIN2780199
Boily, Saikali, Sinnett: Methylation analysis of the glypican 3 gene in embryonal tumours. dans British journal of cancer 2004
Show all 2 Pubmed References
Human Monoclonal Glypican 3 Primary Antibody pour FACS - ABIN4896894
Cartier, Indersie, Lesjean, Charpentier, Hooks, Ghousein, Desplat, Dugot-Senant, Trézéguet, Sagliocco, Hagedorn, Grosset: New tumor suppressor microRNAs target glypican-3 in human liver cancer. dans Oncotarget 2017
Human Monoclonal Glypican 3 Primary Antibody pour CyTOF, FACS - ABIN4899916
Haupt, Murali, Mun, Teplyuk, Mei, Stein, van Wijnen, Nurcombe, Cool: The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. dans Journal of cellular physiology 2009
GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer.
In this study we systematically evaluated a series of CAR constructs targeting glypican-3 (GPC3), which is selectively expressed on several solid tumors. We compared GPC3-specific CARs that encoded CD3zeta (Montrer CD247 Anticorps) (Gz) alone or with costimulatory domains derived from CD28 (Montrer CD28 Anticorps) (G28z), 4-1BB (Montrer TNFRSF9 Anticorps) (GBBz), or CD28 (Montrer CD28 Anticorps) and 4-1BB (Montrer TNFRSF9 Anticorps) (G28BBz).
Data indicate that glypican-3 (GPC3) is an important regulator of epithelial-mesenchymal transition (EMT (Montrer ITK Anticorps)) in breast cancer, and a potential target for procedures against breast cancer metastasis.
Glypican-3 overexpression in Wilms tumor correlates with poor overall survival.
glypican-3 has a role in HBV-related hepatocellular carcinoma
MOSPD1 is a possible candidate gene for DORV (Montrer GDF1 Anticorps), probably in combination with GPC3. Further studies of the combined functions of MOSPD1 and GPC3 are needed, and identification of additional patients with MOSPD1 and GPC3 duplication should be pursued
Glypican-3 is correlated with the clinical malignant behavior of hepatocellular carcinoma and its phenotype changes from positive to negative during tumor cells differentia- tion.
The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with alpha-fetoprotein (Montrer AFP Anticorps).
The lncRNA glypican 3 antisense transcript 1 (GPC3-AS1 (Montrer PTGDR Anticorps)) has been reported to be a potential biomarker for hepatocellular carcinoma (HCC (Montrer FAM126A Anticorps)) screening. We observed a significant upregulation of GPC3-AS1 (Montrer PTGDR Anticorps) in HCC (Montrer FAM126A Anticorps). Increased expression of GPC3-AS1 (Montrer PTGDR Anticorps) was associated with alpha-fetoprotein (Montrer AFP Anticorps), tumor size, microvascular invasion, encapsulation, Barcelona Clinic Liver Cancer stage, and worse prognosis of HCC (Montrer FAM126A Anticorps) patients.
study provides the first evidence that GPC3 can modulate the PCSK9 (Montrer PCSK9 Anticorps) extracellular activity as a competitive binding partner to the LDLR (Montrer LDLR Anticorps) in HepG2 cells.
Data show that notum (Montrer NOTUM Anticorps) and glypican-1 (Montrer GPC1 Anticorps) and glypican-3 gene expression during colorectal cancer (CRC (Montrer SCRIB Anticorps)) development and present evidence to suggest them as potential new biomarkers of CRC (Montrer SCRIB Anticorps) pathogenesis.
Coupling of pGPC3 to liposomes was essential for effective priming of GPC3-specific CTLs.
The expression of GPC-3 was altered by DEN treatment.
Data suggest that GPC3 down-regulates hepatocyte proliferation by binding to hedgehog (Montrer SHH Anticorps) (HH) and down-regulating the HH signaling pathway and binding with CD81 (Montrer CD81 Anticorps), thus making it unavailable to bind to Hhex (Montrer HHEX Anticorps) and causing its nuclear translocation.
Finding represents a rare four layer genomic overlap consisting of growth associated quantitative trait locus (QTL), body mass associated Gpc3 gene, highly conserved miRNA gene and mature miRNA seed SNP identified in the lean mouse.
Hepatocyte overexpression of GPC3 suppresses hepatocyte proliferation and liver regeneration and alters gene expression profiles.
glypican-3 is involved in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma
GPC3 inhibits the PI3K/Akt (Montrer AKT1 Anticorps) anti-apoptotic pathway while it stimulates the p38MAPK (Montrer MAPK14 Anticorps) stress-activated one in murine mammary adenocarcinoma LM3 cells
Gpc3 function in development of Simpson-Golabi-Behmel syndrome is IGF-independent
GPC3 knockout mice exhibit alterations in the Wnt (Montrer WNT2 Anticorps) signaling pathway, which is also associated with the regulation of cell proliferation
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
, glypican proteoglycan 3
, heparan sulphate proteoglycan
, intestinal protein OCI-5
, secreted glypican-3
, defective in Simpson-Golabi-Behmel overgrowth syndrome
, proteoglycan GPC3
, Intestinal protein OCI-5